CLINICAL TRIAL: THE EFFECT OF RISEDRONATE ON BONE TURNOVER AND BONE MASS IN OLDE

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 该提案将研究利塞膦酸钠在骨质流失高危男性人群中的治疗干预。前列腺癌是美国男性中最常诊断的癌症，并且是癌症死亡的第二大原因。在过去的十年中，越来越多的男性正在接受激素抑制疗法治疗局部晚期疾病。最近的研究表明，这种激素抑制与促黄体生成素释放激素（LHRH）激动剂导致快速骨丢失和骨质疏松性骨折的风险增加（1）。老年男性髋部骨折和其他脆性骨折的发病率增加是一个主要的公共卫生问题。髋关节骨折是昂贵的，增加死亡率，并显着损害独立性和生存质量的幸存者。在接受激素抑制治疗的局部晚期前列腺癌患者中，这一问题可能会加剧，这是本研究的基本原理。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This proposal will examine a therapeutic intervention with risedronate in a population of men at high risk for bone loss. Carcinoma of the prostate gland is the most commonly diagnosed cancer in U.S. men, and is the second leading cause of cancer death. Over the last decade, more and more men are being treated with hormonal suppression therapy for locally advanced disease. Recent studies have shown that such hormonal suppression with Luteinizing Hormone Releasing Hormone (LHRH) agonists leads to rapid bone loss and increased risk of osteoporotic fractures (1). The increased incidence of hip fractures and other fragility fractures in older men is a major public health issue. Hip fractures are costly, increase mortality and significantly compromise the independence and quality of life of the survivors. The potential for compounding this problem in men treated with hormonal suppression for locally advanced prostate carcinoma is the rationale for this study.